Madeira Therapeutics Names J. Lyle Bootman to Board of Directors

July 14, 2008

By hammersmith

[Source: Business Wire] – Madeira Therapeutics, a new drug-development company specializing in pediatric pharmaceuticals, has announced the addition of a notable pharmaceutical industry veteran to its Board of Directors. According to Madeira CEO Peter S. Joiner, J. Lyle Bootman, PhD, ScD, Dean of the University of Arizona College of Pharmacy will take an active role in the direction of the company.

Dr. J. Lyle Bootman is professor of pharmacy, medicine and public health, and a Fellow of several professional associations including the American Pharmacists Association, American Association of Pharmaceutical Scientists and the American College of Apothecaries. He is the author of Principles of Pharmacoeconomics and the founding and executive director of the University of Arizona Center for Health Outcomes and PharmacoEconomic (HOPE) Research, one of the first such centers in the world. He is former president of the American Pharmacists Association and President Emeritus of the Pharmacy Therapeutics Society.

Dr. Bootman recently received the 2008 Remington Honor Medal, widely considered the profession’s highest honor.

“This is a significant step in the growth and development of Madeira,” stated Pete Joiner, CEO, Madeira Therapeutics. “Our strategy focuses on the reformulation of pediatric pharmaceuticals for appropriate dosage levels in children. Dr. Bootman is a renowned expert–his knowledge and guidance will serve us well. It is an honor to have him join our Board of Directors.”

Madeira Therapeutics is a new drug-development company specializing in pediatric pharmaceuticals. The Madeira strategy focuses on reformulating approved adult drugs for better dosage control in children. A cholesterol drug is already in the development pipeline and the company has plans to develop formulations for acute pain management and diabetes. Madeira intends to utilize the FDA’s 505(b)(2) approval method, which relies in part on the FDA’s findings for a previously approved drug, thereby shortcutting IND approval by years and tens of millions of dollars. For more information, contact Peter Joiner, (913) 661-1962, or via email at